$NVRO
NEVRO CORP

2015 Q4 Form 10-Q Financial Statement

#000119312515372084 Filed on November 09, 2015

View on sec.gov

Income Statement

Concept 2015 Q4 2015 Q3 2014 Q3
Revenue $33.12M $15.40M $8.668M
YoY Change 240.96% 77.69% 39.85%
Cost Of Revenue $12.80M $5.968M $2.737M
YoY Change 326.67% 118.05% 10.81%
Gross Profit $20.35M $9.434M $5.931M
YoY Change 204.0% 59.06% 59.09%
Gross Profit Margin 61.44% 61.25% 68.42%
Selling, General & Admin $27.60M $21.90M $7.193M
YoY Change 203.3% 204.41% 59.7%
% of Gross Profit 135.61% 232.1% 121.28%
Research & Development $5.900M $5.247M $5.236M
YoY Change 25.53% 0.21% 14.17%
% of Gross Profit 28.99% 55.62% 88.28%
Depreciation & Amortization $320.0K $157.0K $26.00K
YoY Change 966.67% 503.85% 160.0%
% of Gross Profit 1.57% 1.66% 0.44%
Operating Expenses $33.50M $27.14M $12.43M
YoY Change 142.75% 118.38% 36.73%
Operating Profit -$13.14M -$17.71M -$6.498M
YoY Change 84.97% 172.53% 21.19%
Interest Expense -$500.0K $739.0K $0.00
YoY Change 400.0%
% of Operating Profit
Other Income/Expense, Net $0.00 -$922.0K -$1.270M
YoY Change -100.0% -27.4% -391.28%
Pretax Income -$13.60M -$19.19M -$7.748M
YoY Change 65.85% 147.61% 58.61%
Income Tax $600.0K $269.0K $137.0K
% Of Pretax Income
Net Earnings -$14.19M -$19.45M -$7.885M
YoY Change 70.77% 146.72% 57.2%
Net Earnings / Revenue -42.84% -126.31% -90.97%
Basic Earnings Per Share
Diluted Earnings Per Share -$507.1K -$698.9K -$318.5K
COMMON SHARES
Basic Shares Outstanding 27.94M shares 27.88M 1.372M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2015 Q4 2015 Q3 2014 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $193.7M $222.6M $33.69M
YoY Change 9.54% 560.55%
Cash & Equivalents $87.04M $87.56M $14.48M
Short-Term Investments $106.6M $135.0M $19.22M
Other Short-Term Assets $4.000M $3.500M $2.000M
YoY Change 37.93% 75.0%
Inventory $62.43M $42.65M $12.12M
Prepaid Expenses
Receivables $22.52M $10.53M $5.676M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $282.6M $279.2M $53.48M
YoY Change 40.53% 422.06%
LONG-TERM ASSETS
Property, Plant & Equipment $5.794M $5.686M $289.0K
YoY Change 795.52% 1867.47%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.852M $1.901M $2.045M
YoY Change 336.79% -7.04%
Total Long-Term Assets $8.552M $8.493M $2.634M
YoY Change 523.78% 222.44%
TOTAL ASSETS
Total Short-Term Assets $282.6M $279.2M $53.48M
Total Long-Term Assets $8.552M $8.493M $2.634M
Total Assets $291.2M $287.7M $56.11M
YoY Change 43.8% 412.69%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $21.89M $12.91M $3.496M
YoY Change 390.74% 269.34%
Accrued Expenses $14.38M $10.49M $5.116M
YoY Change 129.44% 105.08%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $36.39M $23.50M $8.689M
YoY Change 237.0% 170.41%
LONG-TERM LIABILITIES
Long-Term Debt $19.70M $19.70M $0.00
YoY Change 1.03%
Other Long-Term Liabilities $462.0K $158.0K $67.00K
YoY Change 294.87% 135.82%
Total Long-Term Liabilities $462.0K $158.0K $67.00K
YoY Change 294.87% 135.82%
TOTAL LIABILITIES
Total Short-Term Liabilities $36.39M $23.50M $8.689M
Total Long-Term Liabilities $462.0K $158.0K $67.00K
Total Liabilities $56.59M $43.34M $8.756M
YoY Change 86.0% 395.01%
SHAREHOLDERS EQUITY
Retained Earnings -$189.4M -$175.2M -$113.7M
YoY Change 55.28% 54.17%
Common Stock $424.2M $419.7M $7.662M
YoY Change 44.29% 5377.38%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $234.6M $244.3M -$106.0M
YoY Change
Total Liabilities & Shareholders Equity $291.2M $287.7M $56.11M
YoY Change 43.8% 412.69%

Cashflow Statement

Concept 2015 Q4 2015 Q3 2014 Q3
OPERATING ACTIVITIES
Net Income -$14.19M -$19.45M -$7.885M
YoY Change 70.77% 146.72% 57.2%
Depreciation, Depletion And Amortization $320.0K $157.0K $26.00K
YoY Change 966.67% 503.85% 160.0%
Cash From Operating Activities -$30.42M -$29.40M -$6.920M
YoY Change 232.46% 324.86% 66.35%
INVESTING ACTIVITIES
Capital Expenditures -$700.0K -$2.460M -$60.00K
YoY Change 79.49% 4000.0%
Acquisitions
YoY Change
Other Investing Activities $28.43M $60.31M $4.880M
YoY Change -121.53% 1135.86% 10.41%
Cash From Investing Activities $27.73M $57.85M $4.830M
YoY Change -120.94% 1097.72% 9.28%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 2.240M 580.0K -830.0K
YoY Change -98.53% -169.88% -8400.0%
NET CHANGE
Cash From Operating Activities -30.42M -29.40M -6.920M
Cash From Investing Activities 27.73M 57.85M 4.830M
Cash From Financing Activities 2.240M 580.0K -830.0K
Net Change In Cash -450.0K 29.03M -2.920M
YoY Change -104.17% -1094.18% -1181.48%
FREE CASH FLOW
Cash From Operating Activities -$30.42M -$29.40M -$6.920M
Capital Expenditures -$700.0K -$2.460M -$60.00K
Free Cash Flow -$29.72M -$26.94M -$6.860M
YoY Change 239.27% 292.71% 64.9%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2014Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
15208048 shares
CY2015Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
27936964 shares
CY2014Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
14476000
CY2015Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
290000000 shares
CY2015Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2015Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
27933992 shares
CY2015Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2015Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
376000
CY2015Q3 us-gaap Liabilities Current
LiabilitiesCurrent
23496000
CY2015Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2015Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-119000
CY2015Q3 us-gaap Loss Contingency Accrual At Carrying Value
LossContingencyAccrualAtCarryingValue
0
CY2015Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1901000
CY2015Q3 us-gaap Assets
Assets
287684000
CY2015Q3 us-gaap Assets Fair Value Disclosure Recurring
AssetsFairValueDisclosureRecurring
215352000
CY2015Q3 us-gaap Inventory Net
InventoryNet
42651000
CY2015Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
10525000
CY2015Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5686000
CY2015Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2015Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2015Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2015Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
27933992 shares
CY2015Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2015Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
419649000
CY2015Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1039000
CY2015Q3 us-gaap Long Term Notes Payable
LongTermNotesPayable
19689000
CY2015Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
6846000
CY2015Q3 us-gaap Stockholders Equity
StockholdersEquity
244341000
CY2015Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
158000
CY2015Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
374000
CY2015Q3 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
1891000
CY2015Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
92000
CY2015Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
12912000
CY2015Q3 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
72000
CY2015Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
10492000
CY2015Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-175217000
CY2015Q3 us-gaap Liabilities
Liabilities
43343000
CY2015Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
287684000
CY2015Q3 us-gaap Common Stock Value
CommonStockValue
28000
CY2015Q3 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
906000
CY2015Q3 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
26500000
CY2015Q3 us-gaap Assets Current
AssetsCurrent
279191000
CY2015Q3 us-gaap Cash Uninsured Amount
CashUninsuredAmount
3400000
CY2015Q3 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
134994000
CY2015Q3 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
22400000
CY2015Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3463000
CY2015Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
87558000
CY2015Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
6062000
CY2015Q3 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
16151000
CY2015Q3 nvro Accrued Clinical And Research Expenses Current
AccruedClinicalAndResearchExpensesCurrent
342000
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
12409000
CY2014Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
290000000 shares
CY2014Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2014Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
24865491 shares
CY2014Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2014Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2014Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2014Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
24865491 shares
CY2014Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2014Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
293945000
CY2014Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
205000
CY2014Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
19511000
CY2014Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
4268000
CY2014Q4 us-gaap Stockholders Equity
StockholdersEquity
172070000
CY2014Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
117000
CY2014Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
184000
CY2014Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
998000
CY2014Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
70000
CY2014Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
211000
CY2014Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
4460000
CY2014Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
10000
CY2014Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6268000
CY2014Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-121977000
CY2014Q4 us-gaap Liabilities
Liabilities
30426000
CY2014Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
202496000
CY2014Q4 us-gaap Common Stock Value
CommonStockValue
25000
CY2014Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2014Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
335000
CY2014Q4 us-gaap Liabilities Current
LiabilitiesCurrent
10798000
CY2014Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2014Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
77000
CY2014Q4 us-gaap Loss Contingency Accrual At Carrying Value
LossContingencyAccrualAtCarryingValue
0
CY2014Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
424000
CY2014Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
3000
CY2014Q4 us-gaap Assets
Assets
202496000
CY2014Q4 us-gaap Assets Fair Value Disclosure Recurring
AssetsFairValueDisclosureRecurring
170111000
CY2014Q4 us-gaap Inventory Net
InventoryNet
14856000
CY2014Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
6610000
CY2014Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
647000
CY2014Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
300000
CY2014Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
6896000
CY2014Q4 us-gaap Assets Current
AssetsCurrent
201125000
CY2014Q4 us-gaap Cash Uninsured Amount
CashUninsuredAmount
4300000
CY2014Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
159521000
CY2014Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
151521000
CY2014Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
159313000
CY2014Q4 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
10600000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
5000
us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
455000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
2067000
us-gaap Operating Expenses
OperatingExpenses
35801000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
24358000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
-291000
CY2014Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2851000
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
25287000
CY2014Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
982000
CY2014Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
7960000
CY2014Q4 nvro Accrued Clinical And Research Expenses Current
AccruedClinicalAndResearchExpensesCurrent
613000
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-22000000
us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
50928 shares
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-19.04
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
17769875 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1232439 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
1181511 shares
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
236000
us-gaap Net Income Loss
NetIncomeLoss
-22369000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-22500000
us-gaap Revenues
Revenues
22858000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-775000
us-gaap Operating Income Loss
OperatingIncomeLoss
-21200000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
2458000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
1825000
us-gaap Gross Profit
GrossProfit
14601000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-888000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-263000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-929000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
20767000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-49000
us-gaap Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
-363000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-22549000
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-9000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-21995000
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-40000
us-gaap Investment Income Interest
InvestmentIncomeInterest
93000
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
-473000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
374000
us-gaap Share Based Compensation
ShareBasedCompensation
1234000
us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
131000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
15082000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
605000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
955000
us-gaap Inventory Write Down
InventoryWriteDown
457000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
45361000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
20719000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
319000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
65000
us-gaap Cost Of Revenue
CostOfRevenue
8257000
nvro Payment Of Deferred Offering Costs
PaymentOfDeferredOfferingCosts
1246000
nvro Unpaid Deferred Offering Costs
UnpaidDeferredOfferingCosts
532000
nvro Vesting Of Early Exercised Stock Options
VestingOfEarlyExercisedStockOptions
128000
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-70009000
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 Business
us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
23466 shares
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2015
dei Amendment Flag
AmendmentFlag
false
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.04
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2907426 shares
dei Document Type
DocumentType
10-Q
dei Entity Central Index Key
EntityCentralIndexKey
0001444380
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b>Concentration of Credit Risk and Other Risks and Uncertainties</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash, cash equivalents and investments. The majority of the Company&#x2019;s cash is held by one financial institution in the United States of America in excess of federally insured limits. The Company maintained investments in money market funds that were not federally insured during the periods ended September&#xA0;30, 2015 and December&#xA0;31, 2014. The Company also held cash in foreign banks of approximately $3.4 million at September&#xA0;30, 2015 and $4.3&#xA0;million at December&#xA0;31, 2014 that was not federally insured. The Company has not experienced any losses on its deposits of cash and cash equivalents.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> Historically, substantially all of the Company&#x2019;s revenue has been derived from sales of its products in international markets, principally Australia and Europe. In the international markets in which the Company participates, the Company uses both direct sales forces and distributors to sell its products. Recently, the Company began deriving revenue from customers in the United States, accounting for approximately $4.5 million of its $15.4 million of revenue for the three months ended September&#xA0;30, 2015. The Company performs ongoing credit evaluations of its direct customers and distributors, does not require collateral and maintains allowances for potential credit losses on customer accounts when deemed necessary.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> During the three months and nine months ended September&#xA0;30, 2015 and 2014, no single customer accounted for more than 10% of the Company&#x2019;s revenue. As of September&#xA0;30, 2015 and December&#xA0;31, 2014, no single customer accounted for 10% of the accounts receivable balance.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> The Company is subject to risks common to early-stage medical device companies, including, but not limited to, new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations, product liability, manufacturing quality and scaling, uncertainty of market acceptance of products and the need to obtain additional financing. The Company is dependent on third-party manufacturers and suppliers, in some cases sole- or single-source suppliers.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> There can be no assurance that the Company&#x2019;s products will continue to be accepted in its existing marketplaces, nor can there be any assurance that any future products or services can be developed or manufactured at an acceptable cost and with appropriate performance characteristics, or that such products or services will be successfully marketed, if at all.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> The Company expects to incur substantial operating losses for the next several years and may need to obtain additional financing in order to launch and commercialize any products or product candidates for which it receives regulatory approval. There can be no assurance that such financing will be available or will be at terms acceptable by the Company.</p> </div>
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Registrant Name
EntityRegistrantName
NEVRO CORP
us-gaap Standard Product Warranty Description
StandardProductWarrantyDescription
Limited one- to five-year warranty
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
26126145 shares
dei Document Period End Date
DocumentPeriodEndDate
2015-09-30
us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b>Use of Estimates</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Significant accounting estimates and management judgments reflected in the condensed consolidated financial statements include items such as allowances for doubtful accounts; clinical accruals; stock-based compensation; depreciation and amortization periods; inventory valuation; valuation of investments and deferred tax assets, including valuation allowances. Estimates are based on historical experience, where applicable, and other assumptions believed to be reasonable by the management. Actual results may differ from those estimates under different assumptions or conditions.</p> </div>
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
41000
us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
1260000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
4338000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
127924000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-195000
us-gaap Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
-2576000
us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
606000
dei Trading Symbol
TradingSymbol
NVRO
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
26102679 shares
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
4310000
us-gaap Net Income Loss
NetIncomeLoss
-53240000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-53240000
us-gaap Revenues
Revenues
36482000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
646000
us-gaap Operating Income Loss
OperatingIncomeLoss
-49223000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
29542000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
1483000
us-gaap Gross Profit
GrossProfit
21133000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1757000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
324000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-53435000
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-191000
us-gaap Investment Income Interest
InvestmentIncomeInterest
399000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
1016000
us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
0
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
958000
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-4000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-52674000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
566000
us-gaap Share Based Compensation
ShareBasedCompensation
5083000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
62271000
us-gaap Operating Expenses
OperatingExpenses
70356000
us-gaap Interest Expense
InterestExpense
2093000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
11932000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
120585000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
15508000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
118440000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
3851000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
2145000
us-gaap Inventory Write Down
InventoryWriteDown
2071000
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
179000
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
-237000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
144772000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
54848000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
7994000
us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
287000
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
58000
us-gaap Cost Of Revenue
CostOfRevenue
15349000
nvro Employee Stock Purchase Plan Offering Period
EmployeeStockPurchasePlanOfferingPeriod
P6M
nvro Vesting Of Early Exercised Stock Options
VestingOfEarlyExercisedStockOptions
39000
CY2014 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
31100000
CY2014 us-gaap Net Income Loss
NetIncomeLoss
30700000
CY2014 us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
0
CY2014Q3 us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
42601 shares
CY2014Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-5.96
CY2014Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1372211 shares
CY2014Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
1329610 shares
CY2014Q3 us-gaap Net Income Loss
NetIncomeLoss
-7885000
CY2014Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-7929000
CY2014Q3 us-gaap Revenues
Revenues
8668000
CY2014Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-6498000
CY2014Q3 us-gaap Gross Profit
GrossProfit
5931000
CY2014Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1270000
CY2014Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-38000
CY2014Q3 us-gaap Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
32000
CY2014Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-7967000
CY2014Q3 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-2000
CY2014Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-7748000
CY2014Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-36000
CY2014Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
20000
CY2014Q3 us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
-1291000
CY2014Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
137000
CY2014Q3 us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
44000
CY2014Q3 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
173000
CY2014Q3 us-gaap Operating Expenses
OperatingExpenses
12429000
CY2014Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5236000
CY2014Q3 us-gaap Inventory Write Down
InventoryWriteDown
200000
CY2014Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
7193000
CY2014Q3 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
26000
CY2014Q3 us-gaap Cost Of Revenue
CostOfRevenue
2737000
CY2015Q3 us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
19779 shares
CY2015Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.70
CY2015Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
27881302 shares
CY2015Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
27861523 shares
CY2015Q3 us-gaap Net Income Loss
NetIncomeLoss
-19454000
CY2015Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-19454000
CY2015Q3 us-gaap Revenues
Revenues
15402000
CY2015Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-17709000
CY2015Q3 us-gaap Gross Profit
GrossProfit
9434000
CY2015Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-922000
CY2015Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-277000
CY2015Q3 us-gaap Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
-1170000
CY2015Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-19731000
CY2015Q3 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-89000
CY2015Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-19185000
CY2015Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-188000
CY2015Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
185000
CY2015Q3 us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
293000
CY2015Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
269000
CY2015Q3 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
851000
CY2015Q3 us-gaap Operating Expenses
OperatingExpenses
27143000
CY2015Q3 us-gaap Interest Expense
InterestExpense
739000
CY2015Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5247000
CY2015Q3 us-gaap Inventory Write Down
InventoryWriteDown
500000
CY2015Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
21896000
CY2015Q3 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
157000
CY2015Q3 us-gaap Cost Of Revenue
CostOfRevenue
5968000

Files In Submission

Name View Source Status
0001193125-15-372084-index-headers.html Edgar Link pending
0001193125-15-372084-index.html Edgar Link pending
0001193125-15-372084.txt Edgar Link pending
0001193125-15-372084-xbrl.zip Edgar Link pending
d40030d10q.htm Edgar Link pending
d40030dex311.htm Edgar Link pending
d40030dex312.htm Edgar Link pending
d40030dex321.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
nvro-20150930.xml Edgar Link completed
nvro-20150930.xsd Edgar Link pending
nvro-20150930_cal.xml Edgar Link unprocessable
nvro-20150930_def.xml Edgar Link unprocessable
nvro-20150930_lab.xml Edgar Link unprocessable
nvro-20150930_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending